When should I choose a selective serotonin reuptake inhibitor (SSRI) versus a serotonin‑norepinephrine reuptake inhibitor (SNRI) for treating major depressive disorder, considering efficacy, side‑effect profile, comorbid chronic or neuropathic pain, and risk of hypertension?

SSRI vs. SNRI for Major Depressive Disorder

For uncomplicated major depressive disorder, choose either an SSRI or SNRI based on adverse effect profile, cost, and patient preference—they have equivalent efficacy for depression alone 1. However, if the patient has comorbid chronic pain, neuropathic pain, or fibromyalgia, choose an SNRI (duloxetine or venlafaxine) as first-line therapy 2.

Decision Algorithm

Step 1: Assess for Comorbid Pain Conditions

If chronic or neuropathic pain is present:

• Choose duloxetine (60 mg once daily) as first-line for painful diabetic peripheral neuropathy, fibromyalgia, or chronic musculoskeletal pain 2

  • Start 30 mg daily for 1 week to reduce nausea, then increase to 60 mg daily
  • Does not cause clinically significant blood pressure changes or cardiac conduction abnormalities
  • No need for aminotransferase monitoring per recent reviews 2

• Alternative: venlafaxine (150-225 mg/day) for painful diabetic neuropathy or mixed polyneuropathies 2

  • Requires 2-4 weeks to titrate to therapeutic dose
  • Caution: Can cause dose-dependent hypertension and cardiac conduction abnormalities—monitor blood pressure 2, 3
  • Must taper when discontinuing due to withdrawal syndrome risk 2

If no pain condition exists:

• Choose any SSRI or SNRI based on the criteria below

Step 2: Consider Adverse Effect Profiles

The American College of Physicians guideline establishes that no second-generation antidepressant demonstrates superior efficacy for depression alone 1. Selection should prioritize tolerability:

SSRIs have these specific concerns:

• Higher rates of sexual dysfunction (particularly paroxetine) 1
• Increased risk for nonfatal suicide attempts compared to placebo 1
• Generally ineffective for chronic pain 3, 4

SNRIs have these specific concerns:

• Higher discontinuation rates due to adverse events (3.2% higher than SSRIs) 5
• Venlafaxine specifically: dose-dependent hypertension, requires blood pressure monitoring 2, 3
• Duloxetine: nausea (mitigated by starting at 30 mg) 2

Key advantage of bupropion (not SSRI/SNRI): Lower sexual dysfunction rates than fluoxetine or sertraline 1

Step 3: Evaluate Cardiovascular Risk

If patient has cardiac disease, hypertension, or is >40 years old:

• Avoid venlafaxine due to blood pressure increases and cardiac conduction abnormalities 2, 3
• Duloxetine is safer: no clinically important ECG or blood pressure changes 2
• SSRIs are generally safe for cardiac patients

Step 4: Consider Severity of Depression

For severe depression or SSRI treatment failures:

• Meta-analyses show SNRIs (venlafaxine, duloxetine) have statistically superior efficacy compared to SSRIs in moderate-to-severe depression 6, 7
• The clinical significance is modest: Number Needed to Treat = 24 (meaning 24 patients must be treated with SNRIs instead of SSRIs to obtain one additional responder) 7
• Practical implication: Consider switching from SSRI to SNRI if inadequate response after 6-8 weeks 1

Monitoring and Response Assessment

• Begin monitoring within 1-2 weeks of initiation for suicidal ideation, agitation, or behavioral changes 1
• Assess therapeutic response at 6-8 weeks—if inadequate, modify treatment 1
• Continue treatment 4-9 months after satisfactory response for first episode; longer for recurrent episodes 1

Common Pitfalls to Avoid

1. Don't ignore comorbid pain: This is the clearest differentiator—SNRIs have proven analgesic properties while SSRIs do not 2, 4

2. Don't use venlafaxine without blood pressure monitoring: Dose-dependent hypertension is a real risk, particularly at therapeutic doses (150-225 mg/day) 2, 3

3. Don't abruptly discontinue venlafaxine: Withdrawal syndrome is well-documented—always taper 2

4. Don't expect dramatic efficacy differences for depression alone: The evidence shows equivalent effectiveness for uncomplicated MDD 1, 8

5. Don't overlook sexual dysfunction counseling: This is a major cause of non-adherence, particularly with paroxetine 1

Evidence Nuances

While some meta-analyses suggest modest superiority of SNRIs over SSRIs for depression 5, 6, 7, the most authoritative guideline evidence from the American College of Physicians concludes these differences are statistically significant but not clinically meaningful in real-world practice 1. The exception is when dual neurotransmitter action provides additional benefit for comorbid pain conditions 2, 9, 4.